A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506393-12-00

Enrollment

Registered

2024-01-15

Start date

2024-02-13

Completion date

Unknown

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026